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Abstract: Bladder cancer (BC) is the tenth most frequent cancer worldwide. Due to the need
for recurrent cystoscopies and the lack of non-invasive biomarkers, BC is associated with a high
management burden. In this respect, small non-coding RNAs (sncRNAs) have been investigated
in urine as possible biomarkers for BC, but in plasma their potential has not yet been defined.
The expression levels of sncRNAs contained in plasma extracellular vesicles (EVs) from 47 men with
BC and 46 healthy controls were assessed by next-generation sequencing. The sncRNA profiles
were compared with urinary profiles from the same subjects. miR-4508 resulted downregulated in
plasma EVs of muscle-invasive BC patients, compared to controls (adj-p = 0.04). In World Health
Organization (WHO) grade 3 (G3) BC, miR-126-3p was upregulated both in plasma EVs and urine,
when compared to controls (for both, adj-p < 0.05). Interestingly, two sncRNAs were associated with
the risk class: miR-4508 with a downward trend going from controls to high risk BC, and piR-hsa-5936
with an upward trend (adj-p = 0.04 and adj-p = 0.05, respectively). Additionally, BC cases with low
expression of miR-185-5p and miR-106a-5p or high expression of miR-10b-5p showed shorter survival
(adj-p = 0.0013, adj-p = 0.039 and adj-p = 0.047, respectively). SncRNAs from plasma EVs could be
diagnostic biomarkers for BC, especially in advanced grade.
Keywords: bladder cancer; extracellular vesicles; next-generation sequencing; liquid biopsy; small
non-coding RNA profiling; microRNAs; piRNAs; non-invasive biomarkers
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1. Introduction
Bladder cancer (BC) ranks as the tenth most frequent diagnosed human cancer worldwide, with
549,393 new cases and 199,922 related deaths being reported in 2018, according to the GLOBOCAN
statistics [1].
BC has a marked male predominance, with a 3:1 male-to-female ratio [2]. BC incidence peaks at
an older age (5th to 7th decade) and is strongly connected to the habit of smoking. Occupational and
environmental carcinogens are additional contributing risk factors. BC is more prevalent in countries
with a high human development index [2,3]. Moreover, in some world regions, like Northern and
sub-Saharan Africa, higher prevalence is attributed to the Schistosoma haematobium infection [4].
Based on tissue infiltration, BC is usually divided into two separate entities: non-muscle invasive
bladder cancer (NMIBC), accounting for 70% of the cases, and muscle invasive bladder cancer
(MIBC) [5]. Characteristics for NMIBC are high progression and recurrence rates that require repeated
cystoscopic follow-up [6].
Unlike colorectal or breast cancers, there are no currently available screening programs for BC.
Usual referral symptoms in BC patients are either macroscopic hematuria or urinary tract symptoms
together with microscopic hematuria [4]. Urine cytology, which implies the microscopic examination of
voided urine, is one of the current non-invasive diagnostic tools, albeit with limited utility, because of
the relatively low sensitivity, especially in low-grade tumors (16%) [7]. Therefore, the current gold
standard for diagnosis is represented by cystoscopy and tissue biopsy, an invasive procedure that
causes major patient discomfort [8] and potential adverse effects [6]. The replacement of the invasive
and costly procedure of cystoscopy is one of the main objectives in biomarker development for BC [9].
Researchers have been active in seeking new molecules that could act as biomarkers in either
diagnosis or follow-ups. One such class of molecules are the small non-coding RNAs (sncRNAs).
They are transcripts, less than 200 nucleotides in length, which are not translated into proteins. The most
investigated sncRNAs are microRNAs (miRNAs), 19–22 nucleotide long molecules, which serve
predominantly as post-transcriptional modulators [10]. Among other sncRNAs, Piwi-interacting RNAs
(piRNAs) are slightly longer molecules (26–31 nucleotides) implicated in transposon silencing and
transcriptional regulation [11].
SncRNAs are expressed in tissues, but they can also be isolated from body fluids, where they
can be found either as cell-free circulating molecules (cfRNA) or packed in extracellular vesicles
(EVs), such as exosomes [12]. In recent years, the interest on sncRNAs has increased since they have
been found dysregulated in cancer and they have been identified as potential biomarkers for cancer
diagnosis and monitoring [13].
For BC, due to the direct contact to the tumor and ease of sampling, urine is the most investigated
body fluid, with promising results reported by our group [14]. Other investigators searched for BC
biomarkers also in other readily available body fluids, such as blood-derived plasma or serum. In this
sense, most of the studies investigated cfRNA profiles but there are suggestions to start focusing
on circulating EVs and their cargos [15]. However, the results are still inconclusive and, in general,
the available studies did not investigate the potentiality of these biomarkers in distinguishing among
subtypes of BC [16].
In the present study, we investigated sncRNA profiles by next-generation sequencing (NGS)
in plasma-derived EVs from BC patients and healthy controls with the aim of finding potential
non-invasive biomarkers for the diagnosis and prognosis of BC. Additionally, we compared the current
results with the sncRNA expression data measured in urine from the same patients previously reported
by our group [14] (Figure 1).
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2.2. Sequencing Results
For the aforementioned samples, four library pools (24-indexed samples per pool) were prepared
for deep sequencing. An average of 11 million reads per sample were generated, ranging from 2.4
to 33 million reads. Raw reads were trimmed for adaptor sequence; reads with length less than
14 nucleotides were discarded. An average of 1.2 million reads per sample (from 0.04 to 7.10 million)
were correctly mapped to mature sncRNA sequences collected from miRBase (release 22), piRBase
(version 1.0) and Ensembl (release 91). Considering all samples, an average of 759 unique sncRNAs
(of which 566 miRNAs) were identified and associated with at least one read, ranging from 358 to
1242 unique sncRNAs (from 270 to 968 unique miRNAs). After the mapping step, we created a count
matrix composed by 93 samples and 2408 sncRNAs having at least one read in one sample. Depending
on the selected model (see material and methods section), the number of sncRNAs tested for differential
expression ranged from 474 to 517. A summary of the results is presented in Table S1.
2.3. Differentially expressed sncRNAs in Extracellular Vesicles
We tested several models to assess whether there were differentially expressed sncRNAs in EVs
of BC patients compared to healthy controls. All models were adjusted by batch (library pool), age,
and smoking status. Hereby, we only report associations that are significant after accounting for the
testing of multiple sncRNAs (False Discovery Rate (FDR)).
The first comparison was between all cancer cases and controls, yielding no significant association.
Then, we stratified the cases according to three criteria: tumor type (NMIBC vs. MIBC), and two
histologic gradings (G1 and G2 vs. G3, or LG vs. HG). For each stratification, we compared the
resulting subgroups and each of them against the controls, totaling nine comparisons.
For the tumor type, the only comparison yielding differentially expressed sncRNAs was MIBC
versus controls. Specifically, four miRNAs were downregulated in MIBC: miR-4508 (adj-p = 0.04),
miR-454-5p (adj-p = 0.04), miR-628-3p (adj-p = 0.04), and miR-3140-3p (adj-p = 0.01). However, results
should be taken cautiously since only miR-4508 had high read counts (653 on average) while the other
three miRNAs were much less abundant (less than 20) with miR-3140-3p having 3.2 reads on average
(not shown) (Figure 2A, Table 2).
When considering WHO 1973 histological grading, miR-126-3p resulted upregulated (adj-p = 0.04)
in NMIBC G3 when compared to controls (Figure 2B, Table 2). No differentially expressed sncRNAs
were found comparing NMIBC G1+G2 against G3 or controls.
By stratifying cases according to the more recent WHO 2004 histological grading, the only
significant dysregulated sncRNA was miR-450b-5p, which was significantly downregulated in LG
cases with respect to controls (adj-p = 0.03; Figure 2C, Table 2). The same results were obtained either
including or not MIBC in the HG class (Figure 2C reported the plot including MIBC).
Finally, the associations with the risk class were also tested and two differentially expressed
sncRNAs were found associated: miR-4508 (adj-p = 0.04) with a downward trend going from controls
to high risk and MIBC (class 4) and piR-hsa-5936 (adj-p < 0.05) with an upward trend (Figure 2D,
Table 2).
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Table 2. Summary of differentially expressed sncRNAs across the various comparisons.
sncRNAs Source Comparison Base Mean log2 FC Nominalp-Value
Adjusted
p-Value *
miR-126-3p Plasma EVs G3 vs. CO 3571.00 0.83 8.46 × 10−5 4.43 × 10−2
miR-126-3p Urine G3 vs. CO 101.00 2.41 2.11 × 10−7 1.63 × 10−6
miR-126 Tissue (TCGA) Tumor vs. Normal 5504.14 0.26 9.35 × 10−2 1.31 × 10−1
miR-3140-3p Plasma EVs MIBC vs. CO 3.16 −3.46 2.05 × 10−5 1.06 × 10−2
miR-4508 Plasma EVs MIBC vs. CO 653.24 −1.23 1.62 × 10−4 4.16 × 10−2
miR-4508 Urine MIBC vs. CO 54.28 1.24 9.38 × 10−3 2.48 × 10−2
miR-4508 Plasma EVs Risk class trend 542.91 −0.20 1.12 × 10−4 3.54 × 10−2
miR-4508 Urine Risk class trend 231.79 0.32 1.98 × 10−3 6.40 × 10−3
miR-450b-5p Plasma EVs LG vs. CO 26.10 −1.10 5.92 × 10−5 3.05 × 10−2
miR-450b-5p Urine LG vs. CO 5.26 −0.07 8.96 × 10−1 1.00
miR-450b Tissue (TCGA) Tumor vs. Normal 53.7 −0.59 3.87 × 10−2 5.85 × 10−2
miR-454-5p Plasma EVs MIBC vs. CO 9.99 −1.36 3.22 × 10−4 4.16 × 10−2
miR-454 Tissue (TCGA) Tumor vs. Normal 26.37 −1.05 1.48 × 10−7 6.74 × 10−7
miR-628-3p Plasma EVs MIBC vs. CO 16.58 −1.22 3.09 × 10−4 4.16 × 10−2
miR-628-3p Urine MIBC vs. CO 11.27 2.32 7.84 × 10−5 3.76 × 10−4
miR-628 Tissue (TCGA) Tumor vs. Normal 31.68 0.23 4.18 × 10−1 4.87 × 10−1
piR-hsa-5936 Plasma EVs Risk class trend 37.01 0.29 2.92 × 10−4 4.61 × 10−2
piR-hsa-5936 Urine Risk class trend 540.58 −0.09 2.86 × 10−1 3.89 × 10−1
log2 FC: log2 Fold change; EVs: extracellular vesicles; * FDR significant results in bold. miRNAs in TCGA lack the
specification of -5p or -3p arms. CO = controls; MIBC = muscle-invasive bladder cancer; LG = low grade; EVs =
extracellular vesicles; TCGA = The Cancer Genome Atlas.
2.4. Replication of the Differentially Expressed sncRNAs in Urine of the Same Subjects
We checked if the altered sncRNAs in plasma EVs were also differentially expressed in urine from
the same patients (as already reported in [14]). miR-3140-3p and miR-454-5p were not detected in
urine samples while miR-450b-5p and piR-hsa-5936 were not significantly differentially expressed.
On the other hand, miR-628-3p and miR-4508 were significantly upregulated in urine, in contrast to
plasma where they were downregulated. Only miR-126-3p was significantly upregulated in G3 with
respect to controls in both plasma EVs and urine, with lower expression (~100 reads in average) but
higher fold change in urine (adj-p = 1.04 × 10−5). All the results are reported in Table 2.
2.5. Comparison with miRNA Profiles in Primary Tissues from TCGA
We also checked whether the differentially expressed miRNAs in plasma EVs observed in our
study had similar expression patterns in tissue samples from MIBC patients (the only available) from
The Cancer Genome Atlas (TCGA) project. We compared only tumor paired with normal tissues
from the same individuals. In this case, miR-3140-3p, miR-4508, and piR-hsa-5936 were not expressed
or quantified, while miR-628-3p, miR-450b-5p, and miR-126-3p were detected but not differentially
expressed in tissues. miR-454-5p was significantly downregulated in cancer tissues. In plasma EVs,
miR-454-5p was also downregulated in MIBC against controls (Table 2).
2.6. Functional Implications of Dysregulated miRNAs
We retrieved the validated target genes for the significantly differentially expressed miRNAs
(namely, miR-450b, miR-126-3p, and miR-4508) and performed gene ontology (GO) and pathway
enrichment analyses using the miRWalk 3.0 database and EnrichR separately for each of them.
miR-126-3p has 4 validated target genes (GRIN2B, FOXO3, ADGRE5, and CXCL12). Several terms
were enriched after statistical adjustment for multiple tests including biological processes involving the
regulation of death of neuronal cells (GO Biological Processes: “positive regulation of neuron death”
(GO:1901216), “negative regulation of dendritic cell apoptotic process” (GO:2000669), “regulation
of dendritic cell apoptotic process” (GO:2000668), etc.; (Table S2A) and the inflammatory response
(GO Molecular Functions: “CXCR chemokine receptor binding (GO:0045236)”, “chemokine activity
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(GO:0008009)”, “cytokine receptor binding (GO:0005126)”; KEGG: “Chemokine signaling pathway”,
“NF-κ B signaling pathway”, “Intestinal immune network for IgA production”; Table S2A).
miR-4508 has 12 validated target genes (ASB6, ABL1, YES1, LEPROTL1, VAV3, IRAK3, U2AF2,
PEX26, RGS6, HOOK3, KIAA0754, CAPN15). Enrichment analyses linked these genes to several
GO Biological Process terms including those mediating the immune system response (“Fc-gamma
receptor signaling pathway” (GO:0038094), “Fc-gamma receptor signaling pathway involved in
phagocytosis” (GO:0038096), “Fc receptor mediated stimulatory signaling pathway” (GO:0002431))
and signal transduction (“peptidyl-tyrosine autophosphorylation” (GO:0038083), “transmembrane
receptor protein tyrosine kinase signaling pathway” (GO:0007169), “cellular protein modification
process” (GO:0006464), etc.; for all adj-p < 0.005; Table S2B). Searching in the GO Molecular Functions
database, target genes of miR-4508 were enriched in several terms involved in the modification of
proteins (“protein phosphorylated amino acid binding” (GO:0045309), “phosphotyrosine residue
binding” (GO:0001784), and “protein tyrosine kinase activity” (GO:0004713)).
Finally, miR-450b-5p has 5 validated target genes (SR8SIA3, CNEP1R1, VMA21, POGK, and
RAET1E) which are linked to several pathways and molecular processes, among the others “natural
killer cell mediated cytotoxicity” (KEGG), “natural killer cell lectin-like receptor binding” (GO
Molecular Function, GO:0046703), “alpha-N-acetylneuraminate alpha-2,8-sialyltransferase activity”
(GO Molecular Function, GO:0003828) and “sialyltransferase activity” (GO Molecular Function,
GO:0008373) (Table S2C).
2.7. Predictivity of sncRNAs in BC Diagnosis
We ascertained the predictivity of 661 selected sncRNAs from plasma EVs for the following
binary classification problems: cases versus controls and pairwise comparisons by tumor type (MIBC,
NMIBC and controls) and WHO 1973 histological grade (G3, G1+G2, and controls) (Figure S1; Table S3).
The highest median balanced accuracy (across a ten-fold cross-validation) in distinguishing MIBC
from NMIBC was 0.63 and was obtained by the AdaBoost method testing all sncRNA expression
levels together with age and smoke covariates. The same methods and the same classification were
applied using the altered sncRNAs detected in urine from the same patients. sncRNAs from urine
were consistently at least as predictive as those from plasma EVs and often they performed better
(Figure S1).
2.8. Bladder Cancer Prognosis and Survival
Finally, we performed univariate and multivariate Cox regressions and log-rank test to compare
Kaplan–Meier curves on cancer specific mortality survival (CSM), recurrence/progression-free survival
(RPS), and event-free survival (EFS). All patients for whom the cause of death was uncertain were
removed. In this way, we retained a total of 45 cases. In total, five individuals died for BC, 15 recurred,
one had a progression, and one had both a recurrence event and progressed to MIBC.
After multiple test correction (FDR), significant results were found only for the CSM survival
analyses. In particular, cases with a low expression of miR-185-5p or miR-106a-5p have a higher
risk of death with respect to other cases (log-rank test adj-p = 0.0013 and log-rank test adj-p = 0.039,
respectively; Figure S2A and B). Conversely, cases with a high expression of miR-10b-5p had shorter
survival than other samples (log-rank test adj-p = 0.047; Figure S2C).
miR-185-5p, whose expression shows the strongest association with CSM, targets the 3′-UTRs of
111 validated genes. A Gene Set Enrichment Analysis (GSEA) resulted in interesting GO Biological
Processes (Table S2D), such as “mitotic DNA integrity checkpoint” (adj-p = 0.001), “positive regulation of
cell cycle arrest” (adj-p = 0.001) and “mitotic DNA damage checkpoint” (adj-p = 0.001), thus connecting
this miRNAs with a putative function of a tumor suppressor through the regulation of cell proliferation.
Similarly, WikiPathways 2019 Human database from EnrichR reported the enrichment of miR-185-5p
targets in the pathway “Regulation of Microtubule Cytoskeleton WP2038” (adj-p = 0.003, Table S2D).
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3. Discussion
We investigated by high throughput sequencing technology the sncRNA profiles in plasma
derived EVs in all stages of BC and matched controls, with the aim to find non-invasive biomarkers
that could be a valid alternative to cystoscopy. We observed a downregulation of miR-4508 in MIBC
cases compared to controls and a downward trend of expression for miR-4508 and an upward trend
of expression for piR-hsa-5936 with an increased BC risk class. Finally, we found that the expression
levels of three sncRNAs (miR-185-5p, miR-106a-5p, and miR-10b-5p) are associated with survival in
BC (Figure 1).
Biomarker studies only recently started to focus on the content of EVs. In the past, the main
objects of study in body fluids were free-circulating mRNAs and miRNAs especially as a diagnostic
tool for BC [9]. The new challenge is to analyze the role of other sncRNAs, especially those carried in
EVs, as prognostic and predictive markers [9]. In this respect, the present study focused on profiling by
NGS sncRNAs contained in EVs from plasma. EVs mediate the communication between cancer cells
and the microenvironment supporting the development of the tumor but also preparing pre-metastatic
niche via systemic circulation to distant sites [9,13]. In BC research, urine is the most investigated body
fluid because of the direct contact with the tumor tissue. However, studying circulating sncRNAs in
other body fluids, especially in EVs, could generate better biomarkers for monitoring BC patients and
for their follow up since EVs are secreted by tumor cells in the blood stream to exert an effect in distant
cells [9].
As recently reviewed, there is a broad range of studies focusing on the use of urinary miRNAs as
biomarkers for BC [9,15,17]. Notably, we found only four studies on urine-derived EVs in association
with BC, which reported among the others miR-21-5p [18–20], miR-375 [21], miR-200-family [19,20],
and miR-146 [21,22] as potential diagnostic biomarkers. Few researchers investigated circulating
blood-derived products in BC. For example, Usuba et al. recently proposed a panel of 7 freely-circulating
miRNAs able to discriminate BC from healthy controls and other malignancies with an AUC of 0.98
(sensitivity 95%, specificity 87%) [23]. Data on circulating biomarkers in BC has been summarized by
Khetrapal et al. [24], but to the best of our knowledge, no studies were conducted so far on the role of
sncRNAs contained in EVs derived from plasma/serum neither as diagnostic nor prognostic biomarkers.
According to the available literature, this is also the first study assessing circulating sncRNAs
derived from plasma EVs by NGS for BC. The use of the NGS is an additional advantage: most of the
studies used microarray techniques, which are prone to bias due to dependency on reference genomes
and possible errors in cross-hybridization. On the other hand, with its ability to detect changes at the
nucleotide level, NGS offers more reliable and reproducible results [25].
GO and pathway enrichment analyses on the validated target genes of the dysregulated sncRNAs,
show several cancer-related processes enriched, especially for the validated targets of miR-126-3p.
This miRNA has been previously linked to BC [26] and others cancers [27], as well as to angiogenesis [28,
29]. Grimolizzi et al., for example, reported miR-126-3p to induce cell proliferation and angiogenesis in
non-tumorigenic cells, but also acting at the same time as a tumor suppressor and metastasis inhibitor
by targeting IRS1, EGFL7, Crk, SLC7A513 [30,31]. In non-small-cell lung cancer, the expression levels
of miR-126-3p in plasma decreased with the progressive cancer grade, while increased in serum
exosomes [30]. Since a preferential accumulation of this miRNA in plasma/serum exosomes has been
reported, we could hypothesize that miR-126-3p secretion is an active tumor process, aiming to stimulate
angiogenesis in nearby and distant healthy tissues and facilitating metastasis. Additional functional
studies will be necessary to confirm this role in BC together with further validation of this signal in an
independent cohort. miR-450b-5p has been indicated as an active repressor of stemness in colorectal
cancer [32] and has been involved in the p53 signaling pathway [33]. This miRNA has also been
studied in association with progression of several solid tumors including, lung adenocarcinoma [34],
rectal cancer [35], and prostate cancer [36]. Interestingly, miR-450b-5p has been associated with ageing
being detected in serum-derived exosomes from old rats [37]. Other two sncRNAs, miR-4508 and
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piR-hsa-5936, found dysregulated in plasma EVs by us, have never been associated to BC. Additional
mechanistic studies are warranted to confirm their functions.
Concerning the CSM survival of BC patients, miR-185-5p, miR-106a-5p, and miR-10b-5p expression
levels seem to be relevant for the prognosis of BC patients. In our study, low expression levels of
miR-185-5p and miR-106a-5p or the high expression of miR-10b-5p were associated with a short
survival. miR-185-5p has been already reported in the literature as a potential cancer biomarker for
melanoma [38], prostate [39], and bladder cancer [14,40]. However, the expression rates of this miRNA
are not consistent across studies, thus raising some issues about the possibility to clarify its complex
molecular involvement in tumor progression, also considering the heterogeneity of tissues and cancer
types. As reported in [15,38] and suggested by the target gene enrichments, this miRNA acts as a
regulator of cellular proliferation. Therefore, it is plausible a scenario where its expression levels are
high in correspondence to the urine [14,40] (i.e., to induce cellular proliferation) but this effect is not
visible in plasma.
miR-106a-5p has also been described as a potential suppressor of proliferation, migration, and
invasion of BC cells [41], supporting our finding that low-expression are associated with worse
prognosis. On the other hand, the function of miR-10b-5p is less clear, several studies have validated its
role as a metastasis promoting factor, with aberrant expression across different cancer types [42]. In BC,
the significance of miR-10b-5p remains controversial. On one hand, its overexpression has been linked
to increased migration, invasion, and metastasis in cell lines and animal models [43]. On the other
hand, it was found downregulated in tumor tissues with respect to adjacent normal tissues, and had
no significant effect on prognosis and survival [43,44]. However, the reduced number of deceased
cases (due to the low mortality rate of BC) does not warrant further speculations on their mechanistic
role in BC.
We are aware of some limitations of the present study. In fact, we have included 47 BC patients and
46 age-matched controls which constitute a relatively small sample size. It is not easy to collect a large
study population with multiple tissues and appropriate sampling procedures, and with the exception
of large studies such as TCGA, the other available studies reported similarly sized BC populations.
For the same reason it was not possible to perform any validation on an independent cohort. BC is
almost three times more common in men than in women; therefore, male patients are relatively “easier”
to collect. In this respect, a study only on men may be biased, but at the same time may reduce the
variability in the analysis of a relatively small sample size. Moreover, it has been demonstrated that
women usually are diagnosed with BC in more advanced stages and they have shorter survival times
than men. Some factors associated with a history of cystitis may contribute to or explain the poorer
outcome, regardless of treatment and after adjustment for a range of other prognostic variables [45].
For the future studies, it could be therefore especially useful to expand the analyses on larger cohorts
that will include also women with BC.
Moreover, the overall normalized read counts of the detected miRNAs were relatively low.
This was somewhat expected since it is quite well-known that the amount of isolated RNA carried
by EVs is low [46,47] and, in particular, there is a selection of the miRNAs cargo transported by EVs.
For sncRNA species other than miRNAs, less information is currently available. Finally, although we
hypothesized potential destinations of EVs secreted from BC tumor cells, the target genes of these
sncRNAs were not experimentally determined. More in-depth and mechanistic studies are necessary
to determine the target organs of these differentially expressed circulating sncRNAs.
4. Materials and Methods
4.1. Patients
The study population consisted of 93 men enrolled in the Turin Bladder Cancer Study (TBCS) [48,49].
Out of them, 47 were diagnosed with BC and 46 were age-matched controls. Among BC, 8 were
diagnosed as MIBC and 39 as NMIBC. Patients were all newly diagnosed, histologically confirmed
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cases of BC registered at two Urology Departments of A.O.U. Città della Salute e della Scienza, in Turin
(Italy). Controls were males recruited randomly from patients treated at the same urology departments
for non-neoplastic disease (prostatic hyperplasia, cystitis, and others) or from patients treated at
the medical and surgical departments for hernias, vasculopathies, diabetes, heart failure, asthma,
or other benign diseases. Patients with cancer, liver, or renal diseases, and smoking-related conditions
were excluded. All the patients signed a written consent to participate in the study according to the
Helsinki Declaration.
The study was approved by the Interhospital Ethical Board of San Giovanni
Battista/C.T.O./C.R.F./Maria Adelaide hospitals (Turin, Italy) and the Institutional Review Boards of the
Italian Institute for Genomic Medicine (IIGM). From all study participants, urine and plasma samples
were collected. miRNA expression levels measured in urine have been previously reported in [14]
(Figure 1).
4.2. Histological Grading of Bladder Cancers
Regarding the histologic grading for BC, the 1973, 2004 and 2016 WHO classifications were
considered. The 1973 WHO classification uses cellular and architectural atypia to subgroup NMIBC
patients into three grades: G1, G2, and G3. The 2004/2016 WHO classifications were introduced because
of reported unclear pathological situations of tumors having criteria of belonging to two classes (G1/2
and G2/3). As a consequence, the G1-3 grading was changed into papillary urothelial neoplasm of
low malignant potential (PUNLMP), non-invasive low-grade papillary urothelial carcinoma (LG), and
high-grade papillary urothelial carcinoma (HG), respectively [50].
4.3. Risk Group Stratification
The BC risk classification was also evaluated according to European Urology Association (EUA)
guidelines [5]. Therefore, BC patients were classified into 4 risk classes—low, intermediate, and
high risk, and MIBC based on multiple criteria. Classification criteria included macroscopic (size,
aspect, number of tumors) and microscopic characteristics (invasiveness—T grade, histologic grade,
lympho-vascular invasion).
4.4. Plasma Separation and Extracellular Vesicles Precipitation
For all subjects, human plasma samples were obtained from 5–8 mL of blood centrifuged for
10 min at 1000 rpm. Plasma aliquots (about 200–300 µL each) were then stored at −80 ◦C until use.
EVs were isolated from 200 µL of plasma using the ExoQuick exosome precipitation solution (System
Biosciences, Mountain View, CA, USA) according to the manufacturer’s instructions and [51]. Briefly,
plasma was mixed with 50.4 µL of ExoQuick solution and refrigerated at 4 ◦C overnight (at least 12 h).
The mixture was further centrifuged at 1500 g for 30 min. The EVs pellet was dissolved in 200 µL of
nuclease-free water; RNA was extracted immediately from this solution.
4.5. RNA Extraction and Quality Control
Total RNA from plasma EVs was extracted with the miRNeasy plasma/serum mini kit (Qiagen,
Hilden, Germany) using the QiaCube extractor (Qiagen, Germany). RNA quality and quantity were
verified according to MIQE guidelines [52]. For all samples, RNA concentration was quantified by
Invitrogen Qubit® 4 Fluorometer with Qubit® microRNA Assay Kit (Invitrogen, Milan, Italy).
4.6. Library Preparation for Small RNA-Seq
Small RNA transcripts were converted into barcoded cDNA libraries. Library preparation was
performed with the NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England
BioLabs Inc., USA). For each library, 6 µL of RNA (min 35 ng) were used in all the experimental
procedures as starting material. Each library was prepared with a unique indexed primer so that the
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libraries could all be pooled into one sequencing lane. Multiplex adaptor ligations, reverse transcription
primer hybridization, reverse transcription reaction, and PCR amplification were performed according
to the protocol for library preparation (Protocol E7330, New England BioLabs Inc., Ipswich, MA, USA).
After PCR amplification, the cDNA constructs were purified with the QIAQuick PCR Purification
Kit (Qiagen, Germany) following the modifications suggested by the NEBNext Multiplex Small RNA
Library Prep Protocol and loaded on the Bioanalyzer 2100 (Agilent Technologies, Milan, Italy) using
the DNA High Sensitivity Kit (Agilent, Germany) according to the manufacturer’s protocol. Libraries
were pooled together (24-plex) and further purified with a gel size selection.
A final Bioanalyzer 2100 run with the High Sensitivity DNA Kit (Agilent Technologies, Milan,
Italy) that allows the analysis of DNA libraries regarding size, purity and concentration completed the
workflow of library preparation. The obtained libraries were subjected to the Illumina sequencing
pipeline, passing through clonal cluster generation on a single-read flow cell (Illumina Inc., San Diego,
CA, USA) by bridge amplification on the cBot (TruSeq SR Cluster Kit v3-cBOT-HS, Illumina Inc.) and
50 cycles sequencing-by-synthesis on the HiSeq 2000 (Illumina Inc.) (in collaboration with EMBL, Gene
core facility, Heidelberg, Germany).
4.7. Computational and Statistical Analyses
Raw reads adapter clipping was performed with the Cutadapt software (version 1.18) [53]. Reads
longer than 14 nucleotides were mapped to a sncRNA reference with the bwa alignment software
(version 0.7.17-r1188) [54], using the mem algorithm and a seed length of 10. Only alignments without
mismatches or indels were considered and those with the highest quality were used to assign each
read to a unique sncRNA. Thus, sncRNAs were quantified for each sample and then merged into a
single count matrix, setting missing sncRNAs to zero. Differential expression analysis was performed
with the DESeq2 Bioconductor’s package (version 1.22.2) [55]. For each model, samples with missing
covariates were dropped and only sncRNAs, where at least 70% of the remaining samples had counts
greater than 5, were tested. sncRNAs were considered significantly associated with a condition or a
trend if their p-value, after adjustment for multiple testing by FDR, was below the 0.05 threshold.
miRNA target genes were retrieved by miRWalk 3.0 database [56]. EnrichR was used for GO and
pathway enrichment analyses [57,58].
To confirm that our findings reflected the situation in cancer tissues, we downloaded miRNA
quantifications measured in BC tissue samples and adjacent normal mucosa from the bladder cancer
dataset (BLCA) of the TCGA project. We tested for differential expression between tumor and healthy
tissue samples taken from the same individuals. Since only 19 individuals had both samples available,
we tested only these subgroups of pairs with DESeq2 (as already done in [14]). Unfortunately, the arms
of the mature miRNAs detected (-5p or -3p) were not differentiated or reported in TCGA quantification,
thus we lack this piece of information.
To ascertain the predictivity of sncRNAs, we employed different machine learning methods from
the Python module scikit-learn (version 21.3): logistic regression with lasso and elastic net penalty,
random forest classifier, and AdaBoost classifier. For lasso and elastic net penalties we tested two values
for the C parameter: 1 (the default) and 0.1. Since C is the inverse of the regularization strength, the
0.1 value yields classifiers that use less features. Performance was estimated by ten-fold cross-validation
for ten different permutations of the samples in our dataset. We measured performance with balanced
accuracy (from scikit-learn) since some classes had a very uneven number of samples (e.g., MIBC
versus controls). We discarded sncRNAs that were not expressed in more than half of the samples.
For the remaining species, expression levels were normalized across samples by dividing them by the
98-percentile of the expression of each sample, regularized by f(e) = log(e + 0.01). The regularized
expression levels of each sncRNA were further standardized by computing their z-scores, which were
used as features in the various models. Besides expression levels, the included features were age
(in years) and smoking (as a one-hot-encoded categorical variable).
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To explore the associations of sncRNAs expression with survival, recurrence and progression
occurrence, we evaluated the CSM survival, RPS, and EFS on BC cases. Before conducting the analyses,
we removed all patients for whom the cause of death was uncertain. CSM survival was evaluated as the
time from the diagnosis to the date of death or the last follow-up. In the RPS analyses, we considered
the time from the diagnosis to the first event of either recurrence or progression, whichever came first.
In the EFS, we applied the same criteria of RPS also considering death events.
We performed univariate and multivariate Cox regression, and Kaplan-Meier curves with log-rank
test using coxph and survfit functions in R (packages survival and survminer, R version 3.5.2 [59]).
Multivariate analyses were adjusted for age, smoking status, risk class and sequencing library.
Kaplan–Meier curves and their statistical tests were performed splitting cases into two groups
by their expression levels for each sncRNA. Two thresholds were selected, taking into account the
proportion of events. For instance, in the CSM analysis, there were five events out of 45 cases,
corresponding to 11%. Then, for each sncRNA, two comparisons were performed: the lowest 11%
expressed cases versus the remaining 89% and the top 11% expressed cases against the remaining 89%.
5. Conclusions
In the present study, profiles of selected sncRNAs in plasma EVs were able to distinguish MIBC
from NMIBC, although their accuracy is too low to be useful in practice. We think that sncRNAs from
plasma EVs could have the potential to be used as predictive biomarkers but further studies in larger
cohorts with more balanced classes are necessary (for example with a larger sample size of MIBC or
also including women).
Although significant results regarding miRNAs as diagnostic tools have been proposed in both
blood-derived and urine biospecimen separately, a higher accuracy might be achieved by combining
measurements of different classes of ncRNAs from different body fluids. Indeed, some authors have
already proposed diagnostic biomarker combinations of different RNA classes [60], with excellent
results. Recent advances in this field are promising and await translation into clinical practice.
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